1
|
Balci S, Akbayir S, Bozlu M, Tamer L. Investigation of the relationship between endothelial nitric oxide synthase T786C polymorphism and PSA, PSA derivatives, and prostate cancer in the Turkish population. J Med Biochem 2023; 42:357-363. [PMID: 37814619 PMCID: PMC10560506 DOI: 10.5937/jomb0-33122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 11/03/2022] [Indexed: 10/11/2023] Open
Abstract
Background Prostate cancer is a slowly progressing cancer. However, it has remained a major medical problem for affected men. Risk factors of prostate cancer include age, race, and prostate cancer family history. Prostate cancer may occur at different frequencies between ethnic populations and countries. Currently, studies on genetic risk factors in prostate cancer aetiology have been increasing. Due to the importance of changes in endothelial nitric oxide synthase in carcinogenesis, we aimed to reveal whether eNOS T786C polymorphism is associated with prostate cancer. Methods Archival samples included in this study were whole blood samples taken from patients who were grouped according to prostate biopsy pathology results (BPH, n: 42; PCa, n: 48) and from healthy participants (controls, n:27). DNA was isolated from these whole blood samples and real-time polymerase chain reaction analysis was performed for endothelial nitric oxide synthase T786C polymorphism with LightCycler 480 II. Measured free and total prostate-specific antigen serum levels were evaluated retrospectively. Results There was a statistical difference between patient-healthy control and control-healthy control groups regarding genotype distributions for eNOS T786C hism. Controls were more likely to have TC and CC genotypes and C alleles than the other two groups. Conclusions Compared to other groups, the percentage of the eNOS786C allele in the control group was found to be higher. As a result of these data, it can be thought that carrying the allele may be protective against the disease.
Collapse
Affiliation(s)
- Senay Balci
- Mersin University, Faculty of Medicine, Department of Biochemistry, Yenisehir/Mersın, Turkey
| | - Serin Akbayir
- Kiziltepe State Hospital, Central Laboratory, Mardin, Turkey
| | - Murat Bozlu
- Mersin University Hospital, Department of Urology, Yenisehir/Mersın, Turkey
| | - Lulufer Tamer
- Mersin University, Faculty of Medicine, Department of Biochemistry, Yenisehir/Mersın, Turkey
| |
Collapse
|
2
|
Zhang WT, Zhang GX, Zhao RZ, Gao SS. The potential diagnostic accuracy of circulating microRNAs for prostate cancer: A meta-analysis. Actas Urol Esp 2022; 46:138-149. [PMID: 35260368 DOI: 10.1016/j.acuroe.2021.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 04/20/2021] [Accepted: 05/23/2021] [Indexed: 06/14/2023]
Abstract
OBJECTIVES This meta-analysis has been conducted to evaluate the diagnostic accuracy of circulating microRNAs for the early diagnosis of prostate cancer (PCA). METHODS A systematic literature search was performed (updated to February 18, 2021) in PubMed, EMBASE, Web of Science, Cochrane Library, Wanfang database and China National Knowledge Infrastructure (CNKI) to identify eligible studies. The pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under curve (AUC) of the summary receiver-operating characteristic (SROC) curve were calculated for both overall and subgroup analysis. The meta-regression and subgroup analysis were performed to explore heterogeneity and Deeks' funnel plot was used to assess publication bias. RESULTS One hundred nineteen studies from 33 articles owned 8703 PCA patients and 4914 controls were included in our meta-analysis. The overall sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and area under the curve were 0.79, 0.81, 4.1, 0.26, 16 and 0.87, respectively. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve of miR-21 in diagnosis of PCA were 0.86, 0.90, 8.3, 0.16, 52 and 0.94, respectively. Subgroup analysis suggested that the upregulated miRNA of serum type with large sample size could carry out a better diagnostic accuracy of PCA patients. Moreover, publication bias was not found. CONCLUSIONS Circulating microRNA, especially miR-21, can be used as a promising noninvasive biomarker in the early diagnosis of PCA.
Collapse
Affiliation(s)
- W T Zhang
- Xi'an Daxing Hospital, Shaanxi, China; International Doctoral School, University of Seville, Seville, Spain
| | - G X Zhang
- International Doctoral School, University of Seville, Seville, Spain
| | - R Z Zhao
- Ophthalmology Service, Hospital Hermanos Ameijeiras, La Habana, Cuba
| | - S S Gao
- Xi'an Daxing Hospital, Shaanxi, China; International Doctoral School, University of Seville, Seville, Spain.
| |
Collapse
|
3
|
La posible precisión diagnóstica de los microARN circulantes para el cáncer de próstata: un metaanálisis. Actas Urol Esp 2022. [DOI: 10.1016/j.acuro.2021.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
4
|
HASANOĞLU S, GÖNCÜ B, YÜCESAN E, ATASOY S, KAYALI Y, ÖZTEN KANDAŞ N. Investigating differential miRNA expression profiling using serum and urine specimens for detecting potential biomarkers for early prostate cancer diagnosis. Turk J Med Sci 2021; 51:1764-1774. [PMID: 33550766 PMCID: PMC8569761 DOI: 10.3906/sag-2010-183] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Accepted: 02/06/2021] [Indexed: 12/05/2022] Open
Abstract
Background/aim MicroRNAs (miRNAs) are known up-to-date candidate biomarkers for several diseases. In addition, obtaining miRNA from different body fluids such as serum, plasma, saliva, and urine is relatively easy to handle. Herein we aimed to detect miRNAs as biomarkers for early stage prostate cancer (PC). For this purpose, we used urine and serum samples to detect any significant differences in miRNA profiles between patients and healthy controls. Materials and methods Total ribonucleic acid (RNA) in urine and serum samples were isolated from eight untreated PC patients, thirty healthy individuals were screened for miRNA profile, and candidate miRNAs were validated. Whole urinary and serum miRNA profile was analyzed using Affymetrix GeneChip miRNA 4.0 Arrays. Candidate miRNAs were investigated by stem-loop reverse transcription- polymerase chain reaction. Results When we analyzed the urinary samples of PC patients, 49 miRNAs were detected to be upregulated and 14 miRNAs were found to be downregulated when compared with healthy controls. According to the serum samples, 19 miRNAs were found to be upregulated, and 21 miRNAs were found to be downregulated when compared with healthy individuals as well. Interestingly, we detected only four overlapping miRNAs (MIR320A, MIR4535, MIR4706, MIR6750) that commonly increase or decrease in both serum and urine samples. Among them, MIR320A was found to be downregulated, and MIR4535, MIR4706, and MIR6750 were found to be upregulated for urine samples. However, only MIR6750 was upregulated and the other three miRNAs were downregulated for serum samples. Conclusion Notably, the expression profile of MIR320A was significantly altered in urine specimens of prostate cancer patients. We considered that MIR320A has been evaluated as a valuable biomarker that can be used in the early diagnosis of PC.
Collapse
Affiliation(s)
- Sevde HASANOĞLU
- Experimental Research Center, Bezmialem Vakıf University, İstanbulTurkey
| | - Beyza GÖNCÜ
- Experimental Research Center, Bezmialem Vakıf University, İstanbulTurkey
| | - Emrah YÜCESAN
- Department of Medical Biology, Faculty of Medicine, Bezmialem Vakıf University, İstanbulTurkey
| | - Sezen ATASOY
- Department of Biochemistry, Faculty of Pharmacy, Bezmialem Vakıf University, İstanbulTurkey
| | - Yunus KAYALI
- Department of Urology, Faculty of Medicine, Bezmialem Vakıf University, İstanbulTurkey
| | - Nur ÖZTEN KANDAŞ
- Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Bezmialem Vakıf University, İstanbulTurkey
| |
Collapse
|
5
|
Barbier RH, McCrea EM, Lee KY, Strope JD, Risdon EN, Price DK, Chau CH, Figg WD. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. Sci Rep 2021; 11:10765. [PMID: 34031488 PMCID: PMC8144422 DOI: 10.1038/s41598-021-90143-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Accepted: 04/30/2021] [Indexed: 11/25/2022] Open
Abstract
Understanding mechanisms of resistance to abiraterone, one of the primary drugs approved for the treatment of castration resistant prostate cancer, remains a priority. The organic anion polypeptide 1B3 (OATP1B3, encoded by SLCO1B3) transporter has been shown to transport androgens into prostate cancer cells. In this study we observed and investigated the mechanism of induction of SLCO1B3 by abiraterone. Prostate cancer cells (22Rv1, LNCaP, and VCAP) were treated with anti-androgens and assessed for SLCO1B3 expression by qPCR analysis. Abiraterone treatment increased SLCO1B3 expression in 22Rv1 cells in vitro and in the 22Rv1 xenograft model in vivo. MicroRNA profiling of abiraterone-treated 22Rv1 cells was performed using a NanoString nCounter miRNA panel followed by miRNA target prediction. TargetScan and miRanda prediction tools identified hsa-miR-579-3p as binding to the 3'-untranslated region (3'UTR) of the SLCO1B3. Using dual luciferase reporter assays, we verified that hsa-miR-579-3p indeed binds to the SLCO1B3 3'UTR and significantly inhibited SLCO1B3 reporter activity. Treatment with abiraterone significantly downregulated hsa-miR-579-3p, indicating its potential role in upregulating SLCO1B3 expression. In this study, we demonstrated a novel miRNA-mediated mechanism of abiraterone-induced SLCO1B3 expression, a transporter that is also responsible for driving androgen deprivation therapy resistance. Understanding mechanisms of abiraterone resistance mediated via differential miRNA expression will assist in the identification of potential miRNA biomarkers of treatment resistance and the development of future therapeutics.
Collapse
Affiliation(s)
- Roberto H Barbier
- Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, MD, 20892, USA
| | - Edel M McCrea
- Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, MD, 20892, USA
| | - Kristi Y Lee
- Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, MD, 20892, USA
| | - Jonathan D Strope
- Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, MD, 20892, USA
| | - Emily N Risdon
- Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, MD, 20892, USA
| | - Douglas K Price
- Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, MD, 20892, USA
| | - Cindy H Chau
- Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, MD, 20892, USA
| | - William D Figg
- Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, MD, 20892, USA.
- Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
| |
Collapse
|
6
|
Binal Z, Açıkgöz E, Kızılay F, Öktem G, Altay B. Cross-talk between ribosome biogenesis, translation, and mTOR in CD133+ 4/CD44+ prostate cancer stem cells. Clin Transl Oncol 2019; 22:1040-1048. [PMID: 31630355 DOI: 10.1007/s12094-019-02229-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Accepted: 10/04/2019] [Indexed: 12/18/2022]
Abstract
OBJECTIVE To investigate the gene expression profile of CSCs and to explore the key pathways and specific molecular signatures involved in the characteristic of CSCs. MATERIALS AND METHODS CD133+ /CD44+ CSCs and bulk population (non-CSCs) were isolated from DU-145 cells using fluorescence-activated cell sorting (FACS). We used Illumina HumanHT-12 v4 Expression to investigate gene expression profiling of CSCs and non-CSCs. Protein-protein interaction (PPI) network analysis was performed using the STRING database. Biomarkers selected based on gene expression profiling were visually analyzed using immunofluorescence staining method. An image analysis program, ImageJ®, was used for the analysis of fluorescence intensity. RESULTS In microarray analysis, we found that many ribosomal proteins and translation initiation factors that constitute the mTOR complex were highly expressed. PPI analysis using the 33 genes demonstrated that there was a close interaction between ribosome biogenesis, translation, and mTOR signaling. The fluorescence amount of mTOR and MLST8 were higher in CSCs compared to non-CSCs. CONCLUSIONS The increase in a number of genes associated with ribosome biogenesis, translation, and mTOR signaling may be important to evaluate prognosis and determine treatment approach for prostate cancer (PCa). A better understanding of the molecular pathways associated with CSCs may be promising to develop targeted therapies to prolong survival in PCa.
Collapse
Affiliation(s)
- Z Binal
- Department of Urology, Faculty of Medicine, Ege University School of Medicine, Ege University, Bornova, PO Box: 35100, 35100, İzmir, Turkey
| | - E Açıkgöz
- Department of Histology and Embryology, Faculty of Medicine, Yuzuncu Yıl University, 65080, Van, Turkey
| | - F Kızılay
- Department of Urology, Faculty of Medicine, Ege University School of Medicine, Ege University, Bornova, PO Box: 35100, 35100, İzmir, Turkey.
| | - G Öktem
- Department of Histology and Embryology, Faculty of Medicine, Ege University, 35100, Izmir, Turkey
| | - B Altay
- Department of Urology, Faculty of Medicine, Ege University School of Medicine, Ege University, Bornova, PO Box: 35100, 35100, İzmir, Turkey
| |
Collapse
|
7
|
Dai Y, Li D, Chen X, Tan X, Gu J, Chen M, Zhang X. Circular RNA Myosin Light Chain Kinase (MYLK) Promotes Prostate Cancer Progression through Modulating Mir-29a Expression. Med Sci Monit 2018; 24:3462-3471. [PMID: 29798970 PMCID: PMC5996838 DOI: 10.12659/msm.908009] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND In developed countries, prostate cancer (PCa) is a frequently diagnosed cancer with the second highest fatality rate. Circular RNAs (circRNAs) are a class of endogenous non-coding RNAs (ncRNAs) stably expressed in cells and involved in a series of carcinomas. However, few research studies have reported on the role of circRNAs in PCa. MATERIAL AND METHODS We used qRT-PCR to detect the expression of circMYLK (circRNA ID: hsa_circ_0141940) and miR-29a in PCa tissues and cell lines. MTT, colony formation, and TUNEL assays were performed to analysis the cell viability of PCa cells. Transwell and wound scratch assays were performed to investigate the cell invasion and migration of PCa cells. RESULTS In the present study, we confirmed that circMYLK expression level was significantly higher in PCa samples and PCa cells than in normal tissues and normal prostatic cells. The upregulated circRNA-MYLK promoted PCa cells proliferation, invasion, and migration; however, si-circRNA-MYLK significantly accelerated the PCa cell apoptosis. We also observed that the aforementioned function of circRNA-MYLK on PCa cells was affected through targeting miR-29a. CONCLUSIONS We confirmed circRNA-MYLK was an oncogene in PCa and revealed a novel mechanism underlying circRNA-MYLK in PC progression.
Collapse
Affiliation(s)
- Yuanqing Dai
- Department of Geriatric Surgery, XiangYa Hospital, Central South University, Changsha, Hunan, China (mainland)
| | - Dongjie Li
- Department of International Medical Central, XiangYa Hospital, Central South University, Changsha, Hunan, China (mainland)
| | - Xiong Chen
- Department of International Medical Central, XiangYa Hospital, Central South University, Changsha, Hunan, China (mainland)
| | - Xinji Tan
- Department of Geriatric Surgery, XiangYa Hospital, Central South University, Changsha, Hunan, China (mainland)
| | - Jie Gu
- Department of Geriatric Surgery, XiangYa Hospital, Central South University, Changsha, Hunan, China (mainland)
| | - Mingquan Chen
- Department of Geriatric Surgery, XiangYa Hospital, Central South University, Changsha, Hunan, China (mainland)
| | - Xiaobo Zhang
- Department of Geriatric Surgery, XiangYa Hospital, Central South University, Changsha, Hunan, China (mainland)
| |
Collapse
|
8
|
Yang Y, Yu T, Jiang S, Zhang Y, Li M, Tang N, Ponnusamy M, Wang JX, Li PF. miRNAs as potential therapeutic targets and diagnostic biomarkers for cardiovascular disease with a particular focus on WO2010091204. Expert Opin Ther Pat 2017. [PMID: 28627982 DOI: 10.1080/13543776.2017.1344217] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
INTRODUCTION A number of miRNAs have been reported to be critically involved in the regulation of cardiovascular disease (CVDs). Therefore, the development of potent analogues/inhibitors for miRNAs have thus become a key focus in the present drug discovery. In this review, we discuss the basic research and clinical use of miRNAs as the early diagnosis and therapeutic targets for CVD. We have also focused on the efficiency of therapeutically targeting miR-499, which is considered as one of the most promising molecules for treating CVDs. Areas covered: In this review, we have discussed the patents and patent applications related to miRNAs detected in CVD patients published in recent years. This review also covers the expression pattern of miR-499, as well as it highlights functions of its inhibitors in CVD. We used Google and Pubmed search engines to find relevant patents. Expert opinion: Although a massive number of miRNAs are patented as CVD biomarkers, further work is absolutely required to evaluate the reliable diagnostic values and therapeutic potential of these candidates. Overall, targeting miRNAs is definitely a promising strategy to be investigated for diagnosis and treatment of CVDs in future, however, the delivery system and off-targets effects are still a difficult challenge need to be elucidated.
Collapse
Affiliation(s)
- Yanyan Yang
- a Institue for translational medicine , Qingdao University , Qingdao , People's Republic of China
| | - Tao Yu
- a Institue for translational medicine , Qingdao University , Qingdao , People's Republic of China
| | - Shaoyan Jiang
- b Department of cardiology , The Affiliated Cardiovascular Hospital of Qingdao University , Qingdao , People's Republic of China
| | - Yinfeng Zhang
- a Institue for translational medicine , Qingdao University , Qingdao , People's Republic of China
| | - Mengpeng Li
- a Institue for translational medicine , Qingdao University , Qingdao , People's Republic of China
| | - Ningning Tang
- a Institue for translational medicine , Qingdao University , Qingdao , People's Republic of China
| | - Murugavel Ponnusamy
- a Institue for translational medicine , Qingdao University , Qingdao , People's Republic of China
| | - Jian-Xun Wang
- a Institue for translational medicine , Qingdao University , Qingdao , People's Republic of China
| | - Pei-Feng Li
- a Institue for translational medicine , Qingdao University , Qingdao , People's Republic of China
| |
Collapse
|